|
Directions Regarding Proposal 3
BY EXECUTING AND SUBMITTING THIS PROXY CARD, YOU ARE DEEMED TO CONFIRM THAT YOU ARE NOT A CONTROLLING SHAREHOLDER AND DO NOT HAVE A CONFLICT OF INTEREST (REFERRED TO
AS A “PERSONAL INTEREST” UNDER THE ISRAELI COMPANIES LAW) IN THE APPROVAL OF PROPOSAL 3.
If you believe that you, or a related party of yours, has such a conflict of interest, or if you are a controlling shareholder, and you wish to participate in the vote on
Proposal 3, you should contact Yaron Meyer at yaronm@Mediwound.com, who will instruct you how to submit your vote. In that case, your vote will count towards or against the ordinary majority required for the approval of
Proposal 3, but will not count towards or against the special majority required for the approval of that proposal.
To change the address on your account, please check the box below and indicate your new address in the space below. Please note that changes to the registered name(s) on the account may not be submitted
via this method. ☐
|
|
|
FOR
|
AGAINST
|
ABSTAIN
|
|
|
|
1. Re-election of the following director nominees:
|
|
|
|
|
|
|
|
(a) Nachum Shamir
|
☐
|
☐
|
☐
|
|
|
|
|
(b) Vickie R. Driver
|
☐
|
☐
|
☐
|
|
|
|
|
(c) David Fox
|
☐
|
☐
|
☐
|
|
|
|
|
(d) Shmuel (Milky) Rubinstein
|
☐
|
☐
|
☐
|
|
|
|
|
(e) Stephen T. Wills
|
☐
|
☐
|
☐
|
|
|
|
2. Re-appointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm and authorization of the Company’s Board of Directors to fix its remuneration
|
☐ | ☐ | ☐ |
|||
|
3. Approval of the payment of an annual cash bonus to the Company’s Chief Executive Officer, Mr. Ofer Gonen, in respect of his performance in 2025
|
☐ | ☐ |
☐ |
|||
|
Signature of shareholder
|
Date
|
Signature of shareholder
|
Date
|
|
Note:
|
Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each owner should sign. When signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation, please sign full corporate name by a duly authorized officer, giving full title as such. If the signer is a partnership, please sign in partnership name by authorized person.
|